Kymera Therapeutics CEO Nello Mainolfi sold 50,000 shares for approximately $6.0 million on July 7, 2026, after the stock gained 170% over the prior 12 months. The transaction was executed under a Rule 10b5-1 trading plan adopted on March 24, 2026, involving the exercise of options with a $2.08 strike price and immediate sale at $119.00 per share. Following the sale, Mainolfi retains 666,568 directly held shares worth about $79.5 million and holds an additional 90,000 stock options. Kymera, a clinical-stage biopharmaceutical company with a $9.8 billion market capitalization, is advancing its lead oral degrader KT-621 in Phase 2b trials for atopic dermatitis and asthma, with data expected in 2027.
Kymera Therapeutics IncCEO sold $6M in stock after a 170% run, signaling insider selling.